Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury: A randomized, placebo-controlled pilot study

✍ Scribed by Sergio Sartori; Lucio Trevisani; Ingrid Nielsen; Davide Tassinari; Vincenzo Abbasciano

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 530 KB
• Volume: 78
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19961001)78:7<1477::aid-cncr15>3.0.co;2-x

✦ Synopsis

BACKGROUND.

Chemotherapy ( C n may induce acute mucosal injury to the stomach and duodenum, but its prevention has been scarcely investigated.

METHODS.

One hundred and eighty-two cancer patients with normal stomach and duodenum or having fewer than 3 erosions, selected to be treated with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) (77 breast carcinoma patients) or 5-fluorouracil (5-FU) (105 colon carcinoma patients), were randomly assigned to prophylactic treatment with misoprostol, 400 pg twice a day; omeprazole, 20 mg once a day; or placebo, 1 tablet twice a day. Seven days after the end of the second course of CT, all patients underwent control esophagogastroduodenoscopy. Endoscopic findings were quantified on the basis of an arbitrary score: 0 = normal; 1 = less than 3 erosions; 2 = 3-15 erosions; 3 = more than 15 erosions or ulcer; 4 = giant ulcer (greatest dimension of more than 2 cm) or multiple ulcers with cumulative greatest dimension exceeding 2 cm.